Imbio RV/LV Software vs Tempus ECG-AF
AI Verdict
Choose Imbio RV/LV Software if…
Choose Imbio RV/LV Software if your clinical workflow involves frequent CTPA scans and you need rapid, automated assessment of right and left ventricular dimensions for pulmonary embolism risk stratification. This tool provides objective, AI-driven RV/LV ratios directly from CTPA images, streamlining the diagnostic process without requiring additional user intervention.
View Imbio RV/LV Software →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if you are looking to proactively identify older patients (65+) at an elevated risk of developing new-onset atrial fibrillation within the next year. This AI-powered solution analyzes standard 12-lead ECGs to support earlier detection and enable timely follow-up for patients who could benefit from preventative or early management strategies.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio RV/LV Software | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | Cloud-based, Locally virtualized (virtual machine, Docker), or through partners like Aidoc, Blackford Analysis, and Philips Healthcare. [9, 27] | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio RV/LV SoftwareTool A emphasizes a 'fully automated workflow' requiring no user intervention after scan completion, and integrates seamlessly with standard PACS environments. It also provides clear visual outputs like annotated images and summary PDF reports, which enhance the user experience for clinicians.
Clinical Value
TieBoth tools are FDA-cleared and offer significant clinical value in distinct areas. Tool A provides acute risk stratification for critical pulmonary conditions like pulmonary embolism, while Tool B offers proactive identification of atrial fibrillation risk for earlier intervention. Their respective contributions to patient care are equally impactful within their specialized contexts.
Pricing & Value
Tempus ECG-AFTool B offers a clear and significant value proposition through established CMS reimbursement pathways, including specific CPT codes and a Medicare rate, effective January 1, 2025. This transparency and direct reimbursement mechanism make it easier for healthcare facilities to integrate and financially justify the solution, unlike Tool A which only specifies a subscription-based model without detailed cost or reimbursement information.
Enterprise Readiness
Imbio RV/LV SoftwareTool A demonstrates superior enterprise readiness with its extensive deployment flexibility, supporting cloud, on-premise, and integration with numerous partner platforms such as Nuance, Aidoc, and Siemens Syngo.via. Its explicit DICOM compliance and integration with standard PACS environments further ensure seamless adoption within diverse healthcare IT infrastructures.
Innovation
Tempus ECG-AFTool B exhibits greater innovation by leveraging AI to predict the future onset of atrial fibrillation from standard 12-lead ECGs, shifting from diagnostic interpretation to proactive risk management. This predictive capability, trained on a vast dataset of over 1.5 million ECGs from more than 500,000 patients, represents a significant advancement in AI for preventative healthcare.
Support & Docs
TieWhile both companies provide contact information for support, the structured facts and web searches do not offer sufficient specific details regarding the scope, quality, or availability of support services (e.g., 24/7 support, dedicated account managers, comprehensive online knowledge base) or the depth of documentation for either tool. Therefore, a clear distinction cannot be made.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio RV/LV Software | Tempus ECG-AF |
|---|---|---|
| Company | Imbio | Tempus AI, Inc. |
| Primary Function/Use Case | Automatically measures right and left ventricular diameters from CTPA scans, providing a ratio to aid in risk stratification for pulmonary conditions like pulmonary embolism. | Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Input Data Type | CTPA scans (DICOM compliant) | 12-lead ECG recordings (compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems) |
| Target Patient Population | Patients undergoing CTPA scans for pulmonary conditions. | Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. |
| Key Output/Measurement | Automated measurement of right and left ventricular diameters, calculation and reporting of RV/LV ratio, annotated images showing ventricular measurements, summary PDF reports. | Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months. |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Imbio RV/LV Software and Tempus ECG-AF.